The EU did a Brexit trade deal with the pharma industry: it tried to lock in a perceived short-term price advantage at the expense of everything else. Instead of prioritising the speed and security of supplies at any price, the EU prioritised the price. The EU paid 24% less for the Pfizer vaccine than the US, for example. For the Oxford/AstraZeneca vaccine, the price gap is 45%. The UK almost certainly paid a lot more. It is no wonder that the manufacturers are prioritising orders on a first-come, first-serve basis, and from countries that pay the full price. The price difference is macroeconomically irrelevant. But if vaccine shortages lead to longer lockdowns, the indirect effect of that short-sighted policy will be massive.
Related Articles

Economics
EU’s V-Recovery Barrels On (Downwards): Total labour market slack up to 14%
The EU seasonally adjusted employment rate for people aged 20-64 stood at 72.0%, down by 1.0pp from73.0% in the first quarter 2020.This has been the sharpest quarter-on-quarter decline since the beginning of the time series […]

Fake News
BBC: BFM journalist Rachid M’Barki suspended in scandal linked to Israeli disinformation firm
The daily business of mainstream media and how much of our news is created Read HERE Tal Hanan

Economics
DeStatis: Germany in Recession
DeStatis got it wrong again just in time for a state election. Election over, lie over. Gross domestic product (GDP), 1st quarter of 2023-0.3% on the previous quarter (price, seasonally and calendar adjusted)-0.2% on the […]
Be the first to comment